Biovaxys Technology Shares Outstanding vs. Return On Asset
| BVAXF Stock | USD 0.05 0.01 11.78% |
For Biovaxys Technology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biovaxys Technology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biovaxys Technology Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biovaxys Technology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biovaxys Technology Corp over time as well as its relative position and ranking within its peers.
Biovaxys |
Biovaxys Technology Corp Return On Asset vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Biovaxys Technology's current stock value. Our valuation model uses many indicators to compare Biovaxys Technology value to that of its competitors to determine the firm's financial worth. Biovaxys Technology Corp is number one stock in shares outstanding category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biovaxys Technology's earnings, one of the primary drivers of an investment's value.Biovaxys Return On Asset vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Biovaxys Technology |
| = | 106.72 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Biovaxys Technology |
| = | -0.38 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Biovaxys Return On Asset Comparison
Biovaxys Technology is currently under evaluation in return on asset category among its peers.
Biovaxys Technology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Biovaxys Technology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biovaxys Technology will eventually generate negative long term returns. The profitability progress is the general direction of Biovaxys Technology's change in net profit over the period of time. It can combine multiple indicators of Biovaxys Technology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
Biovaxys Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Biovaxys Technology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biovaxys Technology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biovaxys Technology's important profitability drivers and their relationship over time.
Use Biovaxys Technology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biovaxys Technology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biovaxys Technology will appreciate offsetting losses from the drop in the long position's value.Biovaxys Technology Pair Trading
Biovaxys Technology Corp Pair Trading Analysis
The ability to find closely correlated positions to Biovaxys Technology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biovaxys Technology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biovaxys Technology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biovaxys Technology Corp to buy it.
The correlation of Biovaxys Technology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biovaxys Technology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biovaxys Technology Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biovaxys Technology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Biovaxys Technology position
In addition to having Biovaxys Technology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Biovaxys OTC Stock
To fully project Biovaxys Technology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biovaxys Technology Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biovaxys Technology's income statement, its balance sheet, and the statement of cash flows.